Traws Pharma Inc (TRAW) Stock Price, Quote & News

Company Profile

Traws Pharma, Inc., a clinical-stage biopharmaceutical company, develops small-molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID-19 that are designed to address treatment resistance, such as TRX01 (Ratutrelvir), an inhibitor in development for the treatment of COVID-19; and Tivoxavir marboxil, an endonuclease inhibitor in development for the treatment of bird flu and seasonal influenza. It...

Industry: Biotechnology

Sector: Healthcare

Phone: 267 759 3680

Fax: 267 759 3681

Website: www.trawspharma.com

Address:

12 Penns Trail, Newtown, United States

Rafiullah_100 Sep. 9 at 12:04 AM

$TRAW insider buying its means with positive news the stock is going very high. 1000%

1 · Reply

Poldi38 Sep. 8 at 8:22 PM

$TRAW $2 by week end.

0 · Reply

Twitties00 Sep. 8 at 2:40 PM

$TRAW

0 · Reply

NVDAMillionaire Sep. 8 at 4:13 AM

$TRAW Excellent article that nails exactly where TRAW stands right now. So if you want to update your TRAW knowledge or get acquainted with TRAW, this is a must read. https://beyondspx.com/quote/TRAW/analysis/traws-pharma-unlocking-antiviral-potential-amidst-financial-headwinds-nasdaq-traw

1 · Reply

scbullsandbears Sep. 8 at 3:09 AM

$TRAW $2.36 incoming and with any other positive announcements we could see 3.00 + soon !

0 · Reply

Twitties00 Sep. 7 at 10:49 PM

$TRAW 💎🇺🇸🔥⏳

0 · Reply

Jerryjerryjerry Sep. 6 at 2:03 PM

$TRAW clinical trial has been posted this week https://clinicaltrials.gov/study/NCT07157007?term=ratutrelvir&rank=1

0 · Reply

Twitties00 Sep. 6 at 11:39 AM

$TRAW 💎🇺🇸🔥⏱️⏳🛸

0 · Reply

Twitties00 Sep. 6 at 10:41 AM

$TRAW 🇺🇸💎🔥

0 · Reply

Twitties00 Sep. 6 at 10:39 AM

$TRAW 💎🔥🇺🇸

0 · Reply

Traws Pharma Receives Approval to Proceed with Phase 2 COVID Studies with Ratutrelvir, Expects Results by Year-End 2025

Aug 14, 2025, 1:14 PM EDT - 25 days ago

Traws Pharma, Inc. (TRAW) Q2 2025 Earnings Call Transcript

Aug 14, 2025, 7:00 AM EDT - 25 days ago

Traws Pharma Reports Second Quarter 2025 Results and Business Highlights

Aug 8, 2025, 7:00 AM EDT - 4 weeks ago

Traws Pharma to Report Second Quarter 2025 Financial Results on Thursday, August 14, 2025

Jun 30, 2025, 6:30 AM EDT - 2 months ago

Traws Pharma Advances Antiviral Pipeline with Multiple Regulatory Submissions

Jun 3, 2025, 7:00 AM EDT - 3 months ago

Traws Pharma Announces Publication of Compelling Efficacy data in RDEB SCC Patients Treated with Legacy Oncology Drug Rigosertib

May 27, 2025, 8:00 AM EDT - 3 months ago

Traws Pharma Announces Receipt of FDA Guidance on Tivoxavir Marboxil and Reports Plans for Pursuing Stockpiling for Pandemic Preparedness

May 15, 2025, 7:00 AM EDT - 4 months ago

Traws Pharma Reports First Quarter 2025 Results and Business Highlights

Apr 1, 2025, 8:50 PM EDT - 5 months ago

Traws Pharma, Inc. (TRAW) Virtual Investor Event Transcript

Mar 28, 2025, 4:30 PM EDT - 5 months ago

Traws Pharma Announces Management Updates

Mar 26, 2025, 7:30 AM EDT - 5 months ago

Traws Pharma to Host Investor Event on Bird Flu and COVID Product Candidates Virtual Event to be Held on Monday, March 31, 2025 at 10:00 AM ET

Mar 25, 2025, 7:30 AM EDT - 5 months ago

Traws Pharma's COVID-19 Candidate, Ratutrelvir, Presented at ICAR

Mar 21, 2025, 7:00 AM EDT - 6 months ago

Traws Pharma's Bird Flu Drug Candidate, Tivoxavir Marboxil, Presented at ICAR

Mar 3, 2025, 7:00 AM EST - 6 months ago

Traws Pharma Reports Positive Results from An Accepted Bird Flu Model for Anti-Viral Candidate, Tivoxavir Marboxil

Feb 28, 2025, 7:00 AM EST - 6 months ago

Traws Pharma Regains Compliance with NASDAQ Equity Listing Rule

Jan 23, 2025, 7:00 AM EST - 8 months ago

Traws Pharma Announces Completion of Phase I Studies with Tivoxavir Marboxil, a Single Dose Oral Investigational Drug for the Treatment and Prevention of H5N1 Bird Flu

Jan 10, 2025, 5:55 PM EST - 8 months ago

Expert Systems and Traws Pharma Report Breakthrough in H5N1Bird Flu Antiviral Program

Dec 30, 2024, 8:00 AM EST - 9 months ago

Traws Pharma, Inc. Announces Financing up to $72.6 Million from Leading Healthcare Institutional Investors to Advance Tivoxavir Marboxil Development for H5N1 Bird Flu to Approval

Dec 23, 2024, 12:00 PM EST - 9 months ago

Traws Pharma stock soars 200% on encouraging bird flu drug data

Dec 23, 2024, 7:00 AM EST - 9 months ago

Traws Pharma Announces Progress in Developing Tivoxavir Marboxil for H5N1 Bird Flu

Nov 14, 2024, 4:30 PM EST - 10 months ago

Traws Pharma Provides Business Update and Reports Q3 2024 Financial Results

Oct 8, 2024, 7:30 AM EDT - 11 months ago

Traws Pharma Announces Positive Topline Phase 1 Data for Flu Candidate, Tivoxavir Marboxil

Sep 30, 2024, 7:30 AM EDT - 1 year ago

Traws Pharma Announces Positive Topline Phase 1 Results for COVID Candidate, Ratutrelvir, an Oral Mpro Inhibitor

Sep 20, 2024, 7:30 AM EDT - 1 year ago

Traws Pharma, Inc. Appoints Luba Greenwood to Board of Directors

Sep 17, 2024, 4:05 PM EDT - 1 year ago

Traws Pharma, Inc. Announces Special Shareholders Meeting Results

Aug 20, 2024, 9:02 AM EDT - 1 year ago

Traws Pharma, Inc. (TRAW) Corporate Update Call Transcript

Aug 15, 2024, 7:00 AM EDT - 1 year ago

Traws Pharma Reports Q2 2024 Financial Results, Provides Recent Business Highlights

Aug 14, 2024, 4:30 PM EDT - 1 year ago

Traws Pharma to Host Corporate Update Call on August 15, 2024, at 8:00 AM ET

Apr 2, 2024, 7:15 AM EDT - 1 year ago

Traws Pharma Announces New Employee Inducement Grants

Mar 8, 2024, 8:00 AM EST - 1 year ago

Onconova Therapeutics' Rigosertib Poster Selected for AACR 2024

Dec 8, 2023, 4:05 PM EST - 1 year ago

Onconova Therapeutics' Preclinical Narazaciclib Data at SABCS Highlights Differentiated Anti-Tumor Activity v. Other CDK4/6i's

Nov 28, 2023, 8:00 AM EST - 1 year ago

Onconova Therapeutics to Present at NobleCon19, Noble Capital Markets' Nineteenth Annual Emerging Growth Equity Conference

Nov 14, 2023, 8:18 PM EST - 1 year ago

Onconova Therapeutics, Inc. (ONTX) Q3 2023 Earnings Call Transcript

Nov 14, 2023, 4:05 PM EST - 1 year ago

Onconova Therapeutics Reports Corporate Update and Announces Third Quarter 2023 Financial Results

Nov 7, 2023, 4:05 PM EST - 1 year ago

Onconova Therapeutics to Provide Corporate Update and Announce Third Quarter 2023 Financial Results on November 14, 2023

Nov 2, 2023, 10:37 AM EDT - 2 years ago

Onconova Therapeutics' ASH Poster To Focus on Narazaciclib in MCL

Oct 24, 2023, 8:00 AM EDT - 2 years ago

Onconova Expands Leadership Team with Two Key Appointments

Oct 19, 2023, 8:00 AM EDT - 2 years ago

Promising Preclinical Narazaciclib Data Presented at MCL Meeting

Sep 28, 2023, 8:00 AM EDT - 2 years ago

Onconova Therapeutics to Present a Late-Breaking Abstract on Rigosertib at the 2023 EADV Congress

Sep 6, 2023, 8:00 AM EDT - 2 years ago

Onconova Therapeutics to Participate at the H.C. Wainwright 25th Annual Global Investment Conference

Aug 10, 2023, 9:08 PM EDT - 2 years ago

Onconova Therapeutics, Inc. (ONTX) Q2 2023 Earnings Call Transcript

Jun 14, 2023, 8:00 AM EDT - 2 years ago

Onconova Therapeutics Presents Preclinical Data on Narazaciclib at the 17th International Conference on Malignant Lymphoma

Jun 5, 2023, 8:00 AM EDT - 2 years ago

Onconova Therapeutics Announces Poster Presentation at the American Society of Clinical Oncology Annual Meeting

May 15, 2023, 9:11 PM EDT - 2 years ago

Onconova Therapeutics, Inc. (ONTX) Q1 2023 Earnings Call Transcript

May 15, 2023, 4:18 PM EDT - 2 years ago

Onconova Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update

May 12, 2023, 8:00 AM EDT - 2 years ago

Onconova Therapeutics to Participate in Ladenburg Thalmann Virtual R&D Showcase on Narazaciclib in Endometrial Cancer

May 4, 2023, 4:05 PM EDT - 2 years ago

Onconova Therapeutics to Provide Corporate Update and Announce First Quarter 2023 Financial Results on May 15, 2023

Apr 6, 2023, 4:05 PM EDT - 2 years ago

Onconova Therapeutics Announces the Unexpected Passing of Chief Medical Officer Dr. Mark Gelder

Mar 23, 2023, 8:00 AM EDT - 2 years ago

Onconova Therapeutics and Pangea Biomed Enter into Research Collaboration to Identify Biomarkers of Response to Rigosertib

Mar 16, 2023, 9:56 PM EDT - 2 years ago

Onconova Therapeutics, Inc. (ONTX) Q4 2022 Earnings Call Transcript

Rafiullah_100 Sep. 9 at 12:04 AM

$TRAW insider buying its means with positive news the stock is going very high. 1000%

1 · Reply

Poldi38 Sep. 8 at 8:22 PM

$TRAW $2 by week end.

0 · Reply

Twitties00 Sep. 8 at 2:40 PM

$TRAW

0 · Reply

NVDAMillionaire Sep. 8 at 4:13 AM

1 · Reply

scbullsandbears Sep. 8 at 3:09 AM

$TRAW $2.36 incoming and with any other positive announcements we could see 3.00 + soon !

0 · Reply

Twitties00 Sep. 7 at 10:49 PM

$TRAW 💎🇺🇸🔥⏳

0 · Reply

Jerryjerryjerry Sep. 6 at 2:03 PM

$TRAW clinical trial has been posted this week https://clinicaltrials.gov/study/NCT07157007?term=ratutrelvir&rank=1

0 · Reply

Twitties00 Sep. 6 at 11:39 AM

$TRAW 💎🇺🇸🔥⏱️⏳🛸

0 · Reply

Twitties00 Sep. 6 at 10:41 AM

$TRAW 🇺🇸💎🔥

0 · Reply

Twitties00 Sep. 6 at 10:39 AM

$TRAW 💎🔥🇺🇸

0 · Reply

Twitties00 Sep. 6 at 2:58 AM

$TRAW do not buy this stock!

0 · Reply

StockWolf95 Sep. 6 at 12:34 AM

$TRAW Solid movement congrats if you got in with me. 🐺 Feel free to take profit when you see fit. I may not get my rebuy on the small swing but that’s okay. Still holding my core bag. If it holds Monday we could see $2+ next week.

2 · Reply

Twitties00 Sep. 5 at 7:51 PM

$TRAW 💎🔥

0 · Reply

VonKruska Sep. 5 at 5:40 PM

$TRAW receives approval to move forward with phase 2 COVID studies.

1 · Reply

Poldi38 Sep. 5 at 2:19 PM

$TRAW wiggling, something is in the works.

0 · Reply

Schube1255 Sep. 4 at 11:33 PM

$TRAW $$

0 · Reply

LaNuits Sep. 4 at 3:48 AM

$TRAW $RIME who's your daddy ? I said TRAW PATIENCE buy in entry was 1.40s

1 · Reply

Razor_BTC_F150 Sep. 3 at 10:00 PM

$TRAW Take US to the promised land! 🙏🏽

0 · Reply

StockWolf95 Sep. 3 at 6:54 PM

$TRAW Flipped some here will buy back in again. Still holding core bag and averaged down a little bit. Looking to reenter sub $1.50 for a swing back over $1.60.

0 · Reply

Schube1255 Sep. 3 at 4:14 PM

$TRAW $LAES

0 · Reply

Twitties00 Aug. 30 at 10:57 PM

$TRAW Chief Medical Officer of Traws 💎👇https://www.newsmax.com/amp/newsmax-tv/robert-redfield-mrna-vaccines/2025/08/28/id/1224359/

0 · Reply

Twitties00 Aug. 30 at 8:26 PM

$TRAW 💎ANTIVIRALS💎

0 · Reply

Market Cap	12.64M
Revenue (ttm)	230,000.00
Net Income (ttm)	-166.52M
EPS (ttm)	N/A
PE Ratio	0.02
Forward PE	N/A
Profit Margin	-72,400.00%
Debt to Equity Ratio	0.00

Volume	117,300
Avg Vol	104,170
Day's Range	N/A - N/A
Shares Out	7.06M
Stochastic %K	94%
Beta	1.52
Analysts	Strong Buy
Price Target	$6.00